Diana Francis - BGNE Old VP Compliance
Insider
Diana Francis is VP Compliance of BGNE Old
| Phone | 345-949-4123 |
| Web | https://www.beigene.com |
BGNE Old Management Efficiency
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BGNE Old's management efficiency ratios could be used to measure how well BGNE Old manages its routine affairs as well as how well it operates its assets and liabilities.BGNE Old currently holds 930.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. BGNE Old has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BGNE Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Andreas Orth | Krystal Biotech | 54 | |
| Karen Alderete | Vaxcyte | N/A | |
| MBA JD | Apellis Pharmaceuticals | 52 | |
| Joel Edwards | Ionis Pharmaceuticals | 63 | |
| Jerry Wang | I Mab | N/A | |
| David Glynn | Krystal Biotech | N/A | |
| Darren Gonzales | Ionis Pharmaceuticals | N/A | |
| Grant MBA | Vaxcyte | 57 | |
| Ying Huang | Legend Biotech Corp | 52 | |
| Lori CPA | Legend Biotech Corp | 53 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| Philip Scalzo | Biomarin Pharmaceutical | N/A | |
| Gloria Lin | Krystal Biotech | N/A | |
| Michael LLM | Ascendis Pharma AS | 54 | |
| Jingwu MD | I Mab | 67 | |
| PharmD JD | Arrowhead Pharmaceuticals | 61 | |
| Peter Heerma | Travere Therapeutics | 53 | |
| Timothy Rolph | Akero Therapeutics | 71 | |
| Maria JD | Incyte | 58 | |
| MBA MBA | Incyte | 64 | |
Management Performance
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 |
BGNE Old Leadership Team
Elected by the shareholders, the BGNE Old's board of directors comprises two types of representatives: BGNE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGNE. The board's role is to monitor BGNE Old's management team and ensure that shareholders' interests are well served. BGNE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BGNE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, CoChairman CoFounder | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Chan Lee, General VP | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Titus Ball, VP Officer | ||
| Julia Wang, Executive Officer | ||
| Aaron Rosenberg, CFO Officer | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Daniel Maller, VP Accounting | ||
| Jaspreet MD, Senior Strategy | ||
| Diana Francis, VP Compliance | ||
| Melika Davis, Clinical Head | ||
| Yan Qi, Senior China | ||
| Xiaobin Wu, President COO |
BGNE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BGNE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.14) % | |||
| Current Valuation | 18.78 B | |||
| Shares Outstanding | 97.63 M | |||
| Shares Owned By Insiders | 19.43 % | |||
| Shares Owned By Institutions | 46.90 % | |||
| Number Of Shares Shorted | 1.38 M | |||
| Price To Earning | (16.19) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in BGNE Stock
If you are still planning to invest in BGNE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BGNE Old's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |